



We claim:

1. A compound having the structural formula



- 5 or a pharmaceutically acceptable salt thereof, wherein

R is




R^1 , R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of H, alkyl and alkoxyalkyl;

- 10 R^6 is H, alkyl, hydroxyalkyl or $-\text{CH}_2\text{F}$;

R^7 , R^8 and R^9 are independently selected from the group consisting of H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo and $-\text{CF}_3$;

Z is R^{10} -aryl, R^{10} -heteroaryl or



- 15 R^{10} is 1 to 5 substituents independently selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxy, alkoxy, hydroxyalkyl, hydroxy-alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxy-alkoxy-alkyl-, (di-alkoxy)-alkyl, (hydroxy)-alkoxyalkyl, R^{15} -cycloalkyl, R^{15} -cycloalkylalkyl, cycloalkyl-oxy, cycloalkyl-O-alkoxy, alkyl- SO_2 -, alkyl- SO -, halo, -CN, cyanoalkyl, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, $-\text{OCF}_3$, $-\text{C}(\text{O})\text{R}^{13}$,
 20 $-\text{O}$ -alkylene- $\text{C}(\text{O})\text{OR}^{13}$, $-\text{C}(\text{O})\text{O}$ -alkyl, $-\text{N}(\text{R}^{11})(\text{R}^{12})$, $\text{N}(\text{R}^{11})(\text{R}^{12})$ -alkyl, $\text{N}(\text{R}^{11})(\text{R}^{12})$ -alkoxy, $-\text{C}(\text{O})\text{N}(\text{R}^{13})(\text{R}^{16})$, R^{11} -heteroaryl, R^{15} -heterocycloalkyl, R^{15} -heterocycloalkyl-alkyl, R^{15} -heterocycloalkyl-alkoxy, R^{15} -heterocycloalkyl-oxy, CF_3 -alkylene-O-alkyl, CF_3 -hydroxyalkyl, $(\text{CF}_3)(\text{hydroxy})$ alkoxy, cyano-alkoxy, -alkylene- $\text{C}(\text{O})$ -O-alkyl, $-\text{SO}_2$ - $\text{N}(\text{alkyl})_2$, (cycloalkyl)hydroxyalkyl, (hydroxyalkyl)alkoxy, (dihydroxy)alkyl,
 25 (dihydroxy)alkoxy, $-\text{C}(=\text{NOR}^{17})$ -alkyl and $-\text{C}(=\text{NOR}^{17})$ - CF_3 ;

or two R^{10} groups on adjacent carbon ring atoms together form $-\text{O}-\text{CH}_2-\text{O}-$, $-\text{O}-(\text{CH}_2)_2-\text{O}-$, $-\text{CH}_2-\text{O}-(\text{CH}_2)_2-\text{O}-$, $-\text{O}-(\text{CH}_2)_2-$, $-(\text{CH}_2)_3-\text{O}-$, $-\text{O}-(\text{CH}_2)_3-\text{O}-$, $-(\text{CH}_2)_3-$,

wherein the ring formed by the two R¹⁰ substituents and the ring carbon atoms to which they are attached is substituted by R¹⁶;

or two R¹⁰ groups on adjacent carbon ring atoms together form

5 -N(R¹¹)-C(O)-O-, -N(R¹¹)-C(O)-S-, -(CH₂)₂CH(OR¹⁸)-, -CH₂CH(OR¹⁸)CH₂-,
-(CH₂)₃CH(OR¹⁸)-, -(CH₂)₂CH(OR¹⁸)CH₂-, -(CH₂)₂C(O)-, -CH₂C(O)CH₂-, -(CH₂)₃C(O)-,
-(CH₂)₂C(O)CH₂-, -O(CH₂)₂CH(OR¹⁸)- or -OCH₂CH(OR¹⁸)CH₂-, wherein the ring
formed by two R¹⁰ substituents and the ring carbon atoms to which they are attached
is optionally substituted on a carbon atom by hydroxyalkyl or alkoxyalkyl;

each R¹¹ is independently selected from the group consisting of H and alkyl;

10 each R¹² is independently selected from the group consisting of H, alkyl,
hydroxyalkyl, alkoxyalkyl, -C(O)-alkyl, -C(O)O-alkyl, (alkoxy)hydroxyalkyl, alkoxyalkyl-
C(O)-, -SO₂alkyl, -alkylene-C(O)alkyl and -alkylene-C(O)O-alkyl;

R¹³ is H, alkyl or -CF₃;

R¹⁴ is H, alkyl, alkoxyalkyl, alkyl-C(O)- or alkoxy-C(O)-;

15 R¹⁵ is 1 to 3 substituents independently selected from the group consisting of
H, alkyl, -OH, alkoxy, alkoxyalkyl and hydroxyalkyl; or two R¹⁵ substituents, taken
together with the carbon to which they are both attached, form a -C(=O)- group;

R¹⁶ is H, alkyl, alkoxyalkyl, OH or hydroxyalkyl;

R¹⁷ is H or alkyl; and

20 R¹⁸ is H or alkyl.

2. A compound of claim 1 wherein R is -C≡CR⁶.

25 3. A compound of claim 2 wherein R⁶ is H or alkyl.

4. A compound of claim 1 wherein R², R³, R⁴ and R⁵ are each H.

5. A compound of claim 1 wherein Z is R¹⁰-aryl or R¹⁰-heteroaryl.

30 6. A compound of claim 5 wherein Z is R¹⁰-phenyl.

7. A compound of claim 6 wherein R¹⁰ is 1, 2 or 3 substituents independently
selected from the group consisting of H, halo, -C(O)R¹³, alkyl, alkoxy, hydroxyalkyl,
(cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl, and cyanoalkyl.

8. A compound of claim 7 comprising two R^{10} substituents wherein one R^{10} is halo and the other R^{10} is halo, $-C(O)R^{13}$, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

5 9. A compound of claim 8 comprising two R^{10} substituents wherein one R^{10} is α -fluoro and the other R^{10} is halo, $-C(O)R^{13}$, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

10. A compound of claim 5 wherein Z is R^{10} -heteroaryl.

10

11. A compound of claim 10 wherein Z is R^{10} -benzoxazolyl or R^{10} -benzisoxazolyl and R^{10} is 1 or 2 substituents independently selected from the group consisting of H, halo and alkyl.


15 12. A compound of claim 11 wherein one R^{10} is fluoro and one R^{10} is methyl.

13. A compound of claim 1 wherein R is $-C\equiv CR^6$, R^2 , R^3 , R^4 and R^5 are each H, and Z is R^{10} -aryl or R^{10} -heteroaryl.


20 14. A compound of claim 13 wherein Z is R^{10} -phenyl and R^{10} is two substituents wherein one R^{10} is halo and the other R^{10} is halo, $-C(O)R^{13}$, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

25 15. A compound of claim 13 wherein Z is R^{10} -benzoxazolyl or R^{10} -benzisoxazolyl and R^{10} is 1 or 2 substituents independently selected from the group consisting of H, halo and alkyl.

16. A compound of claim 1 selected from the group consisting of



30



20. A method of claim 18 for treating Parkinson's disease, senile dementia, psychoses of organic origin, attention deficit disorder, Extra Pyramidal Syndrome, dystonia, restless leg syndrome or periodic limb movement in sleep.

5 21. A pharmaceutical composition comprising a therapeutically effective amount of a combination of a compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease in a pharmaceutically acceptable carrier.

10 22. A method of treating Parkinson's disease comprising administering to a mammal in need of such treatment an effective amount of a combination of a compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease.

15 23. The method of claim 22 wherein the other agents are selected from the group consisting of L-DOPA, dopaminergic agonists, MAO-B inhibitors, DOPA decarboxylase inhibitors and COMT inhibitors.